Ieq Capital LLC Takes $906,000 Position in ICU Medical, Inc. $ICUI

Ieq Capital LLC purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 6,178 shares of the medical instruments supplier’s stock, valued at approximately $906,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ICUI. BlackRock Inc. purchased a new stake in ICU Medical during the 2nd quarter worth approximately $550,250,000. Vanguard Group Inc. lifted its position in shares of ICU Medical by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after acquiring an additional 89,755 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock valued at $345,607,000 after acquiring an additional 99,256 shares in the last quarter. Millennium Management LLC boosted its stake in shares of ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after acquiring an additional 690,694 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of ICU Medical by 6.8% in the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after acquiring an additional 63,026 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Price Performance

ICUI stock opened at $175.10 on Friday. ICU Medical, Inc. has a 1 year low of $112.50 and a 1 year high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The firm has a market capitalization of $4.38 billion, a PE ratio of 148.39, a price-to-earnings-growth ratio of 2.27 and a beta of 0.74. The business has a 50 day simple moving average of $163.95 and a 200-day simple moving average of $143.89.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm’s revenue was up .5% compared to the same quarter last year. During the same quarter last year, the business posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts anticipate that ICU Medical, Inc. will post 7.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. BTIG Research lifted their target price on shares of ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Piper Sandler upped their target price on shares of ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, KeyCorp raised their price target on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, ICU Medical currently has a consensus rating of “Moderate Buy” and an average price target of $192.80.

Insider Buying and Selling

In other news, VP Daniel Woolson sold 5,417 shares of ICU Medical stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the transaction, the vice president owned 17,062 shares in the company, valued at $3,093,852.46. The trade was a 24.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elisha W. Finney sold 378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total transaction of $68,977.44. Following the transaction, the director directly owned 4,871 shares in the company, valued at approximately $888,860.08. The trade was a 7.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 16,974 shares of company stock valued at $3,085,844 over the last 90 days. Insiders own 2.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.